New stock news | It is reported that Yilian Biological has appointed CICC, Goldman Sachs, and Morgan Stanley to handle its Hong Kong listing, with plans to raise over 100 million US dollars.

According to the Zhitong Finance APP, it was reported that Yilian Biotech has appointed China International Capital Corporation (CICC), J.P. Morgan, and Morgan Stanley to handle its Hong Kong IPO, with plans to raise over 100 million US dollars. Previous reports indicated that Yilian Biotech could potentially go public in Hong Kong as soon as 2026.